

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

June 2020



© 2020 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital 608 - 1081 Burrard Street Vancouver, BC V6Z 1Y6

Tel: 604.806.8515 Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677 St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222 Website: www.cfenet.ubc.ca Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







# **EXECUTIVE SUMMARY**

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







# TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

# 4. Health Authority Tables

### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

### ABORIGINAL

4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

# 5. Appendix

5.1 Drug Names and Definitions










June 2020

### 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

N = 7386



Health Authority	Male	Female	All	
FRASER	1459	449	1908	
INTERIOR	420	103	523	
NORTHERN	131	85	216	
VANCOUVER COASTAL	3310	456	3766	
VANCOUVER ISLAND	787	155	942	
	6107	1248	7355	
		Unknown/not stated:	31	
		Total:	7386	

### **Definitions:**

On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






Monthly Report

1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (June 2015 - June 2020)

This document is best viewed in colour.

Drug definitions available in the back.



Ministry of Health

BRITISH COLUMBIA




rovidence

HEALTH CARE

How you want to be treated.

Monthly Report




1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (June 2015 - June 2020)

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS

HEALTH CARE How you want to be treated.



Monthly Report



<sup>1.4</sup> BC-CfE Enrollment: Net Number of New Antiretroviral Participants (June 2015 - June 2020)

Number of Participants


BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS

E **E Forvidence** HEALTH CARE How you want to be treated.



Monthly Report





Ministry of Health

BRITISH COLUMBIA


ovidence

CARE

How you want to be treated.



Monthly Report




1.6 Percent Distribution of Active Participants by CD4 Count (June 2015 - June 2020)







Monthly Report




1.7 Percent Distribution of Inactive Participants by CD4 Count (June 2015 - June 2020)






Monthly Report

1.8 Active and Inactive Participants (June 2015 - June 2020)





Monthly Report



1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (June 2015 - June 2020)








Monthly Report

in HIV/AIDS

How you want to be treated.






Health

Drug definitions available in the back.

# Monthly Report





Date



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





This document is best viewed in colour. Drug definitions available in the back.


(June 2015 - June 2020)

# Monthly Report

in HIV/AIDS

How you want to be treated.







Drug definitions available in the back.



Monthly Report

# 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT





Date




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Monthly Report



1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (June 2015 - June 2020)

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






Monthly Report



(June 2015 - June 2020)



Date

Ministry of Health




Number of Participants

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS

NCE **Providence** HEALTH CARE How you want to be treated.





Ministry of

Health


BRITISH

COLUMBIA

rovidence

HEALTH CARE

How you want to be treated.




Monthly Report

**CENTRE** for **EXCELLENCE** 

in HIV/AIDS



Monthly Report




1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT


BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS








Monthly Report





Date





BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






Monthly Report





Monthly Report

in HIV/AIDS



BRITISH

COLUMBIA


How you want to be treated.

1.20 **Cumulative Resistance Testing Results by Resistance Category** (June 2015 - June 2020)

Drug definitions available in the back.

Monthly Report







# 2.1 Duration of ARV treatment in the Province of BC, 1987-2020 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Curr (n)	rent CD4 Median		ent PVL Median	Current ARV Median
1987	28	5	0	5	2	580	4	62	3
1988	29	6	0	6	4	350	6	<40	3
1989	27	52	1	53	32	460	47	<40	3
1990	26	55	1	56	34	540	50	<40	3
1991	26	37	3	40	16	650	32	<40	3
1992	26	61	5	66	35	640	59	<40	3
1993	25	128	15	143	103	550	125	<40	3
1994	23	80	12	92	62	575	84	<40	3
1995	23	131	22	153	103	580	125	<40	3
1996	21	332	52	384	240	590	332	<40	3
1997	19	275	34	309	202	655	267	<40	3
1998	19	192	43	235	150	595	199	<40	3
1999	19	158	38	196	119	560	164	<40	3
2000	19	120	34	154	98	620	125	<40	3
2001	18	115	29	144	91	580	114	<40	3
2002	17	122	26	148	97	580	124	<40	3
2003	17	148	30	178	110	620	148	<40	3
2004	16	151	39	190	122	610	156	<40	3
2005	15	183	47	230	155	630	192	<40	3
2006	14	175	40	215	143	630	186	<40	3
2007	13	241	49	290	187	630	243	<40	3
2008	12	275	65	340	223	640	284	<40	3
2009	11	301	67	368	228	635	308	<40	3
2010	10	276	74	350	225	650	291	<40	3
2011	9	325	73	398	250	665	326	<40	3
2012	8	268	66	334	213	720	275	<40	3
2013	7	270	65	335	218	675	279	<40	3
2014	6	283	54	337	204	685	275	<40	3
2015	5	283	47	330	203	690	264	<40	3
2016	4	273	54	327	199	640	264	<40	3
2017	3	222	34	256	177	620	214	<40	3
2018	2	203	55	258	184	670	234	<40	3

### **Definitions:**

On treatment defined as being on ARV therapy in the specified month and not reported deceased **Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption **Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent) **Current ARV** defined as number of ARV drugs in the current regimen



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







# 2.1 Duration of ARV treatment in the Province of BC, 1987-2020 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All		ent CD4 Median		ent PVL Median	Current ARV Median
2019	1	242	48	290	214	600	259	<40	3
2020	0	126	28	154	132	600	145	<40	3
Total:	-	6114	1250	7364					

#### **Definitions:**

On treatment defined as being on ARV therapy in the specified month and not reported deceased **Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption **Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent) **Current ARV** defined as number of ARV drugs in the current regimen



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







### 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	7393	788	2456	<40	2146	610
FEB-2019	7368	797	1854	<40	1583	620
MAR-2019	7407	790	2085	<40	1753	610
APR-2019	7358	797	2141	<40	1746	610
MAY-2019	7416	792	2127	<40	1766	620
JUN-2019	7358	803	1926	<40	1593	620
JUL-2019	7370	813	2111	<40	1695	620
AUG-2019	7366	809	2106	<40	1621	600
SEP-2019	7338	806	2011	<40	1567	600
OCT-2019	7389	785	2140	<40	1745	620
NOV-2019	7342	780	2025	<40	1579	630
DEC-2019	7343	777	1700	<40	1289	610
JAN-2020	7357	774	2226	<40	1711	610
FEB-2020	7331	779	1882	<40	1403	626
MAR-2020	7388	770	1628	<40	1182	620
APR-2020	7415	771	770	<40	553	600
MAY-2020	7411	776	1187	<40	812	610
JUN-2020	7386	783	1559	<40	1030	620

#### **Definitions:**

Active patient defined as being on ARV treatment in the specified month Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period) PVL and CD4 tests defined as tests done in the specified month









### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	627	193	73	73	65	350
FEB-2019	658	156	75	108	66	590
MAR-2019	629	167	74	636	61	400
APR-2019	671	157	81	<50	71	480
MAY-2019	617	201	78	87	69	450
JUN-2019	680	158	79	<40	72	530
JUL-2019	668	161	71	<40	58	525
AUG-2019	687	166	81	<40	68	515
SEP-2019	717	152	96	<40	79	580
OCT-2019	659	194	81	102	69	470
NOV-2019	680	180	69	<40	59	560
DEC-2019	666	181	58	<40	49	480
JAN-2020	641	191	71	255	46	435
FEB-2020	680	179	72	<40	58	480
MAR-2020	638	196	54	<40	37	470
APR-2020	611	212	25	107	18	575
MAY-2020	624	203	42	<50	29	490
JUN-2020	657	191	57	<40	44	485

### **Definitions:**

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs) Days off therapy defined as number of days elapsed since last ARV treatment PVL and CD4 tests defined as tests done in the specified month







Monthly Report

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2019	7364	627	14	20	191	159	35	13564
FEB-2019	7349	658	7	16	160	181	-15	13593
MAR-2019	7371	629	15	13	187	150	22	13613
APR-2019	7325	671	10	15	152	182	-46	13641
MAY-2019	7389	617	11	21	197	137	64	13683
JUN-2019	7329	680	14	13	136	191	-60	13704
JUL-2019	7343	668	13	13	181	164	14	13727
AUG-2019	7338	687	12	18	170	174	-5	13763
SEP-2019	7310	717	14	15	181	204	-28	13790
OCT-2019	7323	659	3	13	223	150	13	13819
NOV-2019	7316	680	9	17	165	170	-7	13852
DEC-2019	7312	666	8	12	164	156	-4	13879
JAN-2020	7329	641	10	12	182	155	17	13902
FEB-2020	7297	680	12	19	141	171	-32	13938
MAR-2020	7359	638	14	23	211	154	62	13974
APR-2020	7389	611	12	8	161	124	30	13999
MAY-2020	7391	624	10	15	130	129	2	14024
JUN-2020	7364	657	8	9	123	148	-27	14041

# 2.4 BC-CfE Enrollment

#### **Definitions:**

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Monthly Report

# 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2019	55	6800	485	53	7393	0.74%	91.98%	6.56%	0.72%	100.00%
FEB-2019	54	6775	490	49	7368	0.73%	91.95%	6.65%	0.67%	100.00%
MAR-2019	60	6808	489	50	7407	0.81%	91.91%	6.60%	0.68%	100.00%
APR-2019	57	6764	489	48	7358	0.77%	91.93%	6.65%	0.65%	100.00%
MAY-2019	56	6824	491	45	7416	0.76%	92.02%	6.62%	0.61%	100.00%
JUN-2019	58	6771	481	48	7358	0.79%	92.02%	6.54%	0.65%	100.00%
JUL-2019	61	6772	489	48	7370	0.83%	91.89%	6.64%	0.65%	100.00%
AUG-2019	60	6775	481	50	7366	0.81%	91.98%	6.53%	0.68%	100.00%
SEP-2019	57	6744	486	51	7338	0.78%	91.91%	6.62%	0.70%	100.00%
OCT-2019	61	6788	488	52	7389	0.83%	91.87%	6.60%	0.70%	100.00%
NOV-2019	60	6746	486	50	7342	0.82%	91.88%	6.62%	0.68%	100.00%
DEC-2019	61	6756	478	48	7343	0.83%	92.01%	6.51%	0.65%	100.00%
JAN-2020	59	6757	485	56	7357	0.80%	91.84%	6.59%	0.76%	100.00%
FEB-2020	58	6738	476	59	7331	0.79%	91.91%	6.49%	0.80%	100.00%
MAR-2020	60	6791	486	51	7388	0.81%	91.92%	6.58%	0.69%	100.00%
APR-2020	61	6820	483	51	7415	0.82%	91.98%	6.51%	0.69%	100.00%
MAY-2020	60	6819	481	51	7411	0.81%	92.01%	6.49%	0.69%	100.00%
JUN-2020	59	6791	485	51	7386	0.80%	91.94%	6.57%	0.69%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

## 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

		lamiv	udine			aba	cavir			zidovu	dine			stavu	Idine			didan	osine		te	nofovi	r <taf< th=""><th>&gt;</th><th>te</th><th>nofovi</th><th>r <tdi< th=""><th>-&gt;</th></tdi<></th></taf<>	>	te	nofovi	r <tdi< th=""><th>-&gt;</th></tdi<>	->
	Init	ial	All		Init	ial	All		Initi	al	All		Initi	al	All		Initi	ial	All		Init	tial	All		Ini	tial	All	
JAN-2019	8	23%	3467	48%	7	20%	3254	45%	1	3%	45	1%	0	0%	4	0%	0	0%	1	0%	1	3%	519	7%	26	74%	3358	47%
FEB-2019	13	45%	3457	48%	12	41%	3256	45%	0	0%	44	1%	0	0%	1	0%	0	0%	1	0%	3	10%	541	8%	13	45%	3306	46%
MAR-2019	6	30%	3470	48%	6	30%	3274	45%	0	0%	43	1%	0	0%	2	0%	0	0%	0	0%	2	10%	559	8%	12	60%	3305	46%
APR-2019	12	43%	3469	48%	12	43%	3278	46%	0	0%	43	1%	0	0%	2	0%	0	0%	0	0%	2	7%	586	8%	14	50%	3245	45%
MAY-2019	14	34%	3498	48%	14	34%	3308	46%	0	0%	43	1%	0	0%	2	0%	0	0%	1	0%	4	10%	593	8%	23	56%	3258	45%
JUN-2019	3	14%	3479	49%	3	14%	3291	46%	0	0%	43	1%	0	0%	2	0%	0	0%	1	0%	2	10%	608	8%	16	76%	3198	45%
JUL-2019	8	36%	3504	49%	8	36%	3325	46%	0	0%	38	1%	0	0%	1	0%	0	0%	1	0%	1	5%	625	9%	13	59%	3177	44%
AUG-2019	14	39%	3515	49%	12	33%	3340	47%	2	6%	41	1%	0	0%	1	0%	0	0%	1	0%	2	6%	630	9%	20	56%	3144	44%
SEP-2019	5	19%	3494	49%	5	19%	3318	46%	0	0%	39	1%	0	0%	1	0%	0	0%	1	0%	5	19%	653	9%	17	63%	3121	44%
OCT-2019	4	14%	3513	49%	2	7%	3331	46%	0	0%	38	1%	0	0%	1	0%	0	0%	1	0%	1	4%	668	9%	23	82%	3142	44%
NOV-2019	8	24%	3458	48%	7	21%	3281	46%	1	3%	37	1%	0	0%	1	0%	0	0%	1	0%	6	18%	728	10%	19	58%	3113	44%
DEC-2019	1	4%	3437	48%	1	4%	3259	46%	0	0%	37	1%	0	0%	1	0%	0	0%	1	0%	13	48%	855	12%	13	48%	3051	43%
JAN-2020	2	9%	3403	47%	2	9%	3227	45%	0	0%	34	0%	0	0%	1	0%	0	0%	0	0%	9	39%	1024	14%	12	52%	2962	41%
FEB-2020	3	8%	3354	47%	3	8%	3182	45%	0	0%	33	0%	0	0%	1	0%	0	0%	0	0%	16	44%	1169	16%	17	47%	2825	40%
MAR-2020	5	14%	3326	46%	5	14%	3161	44%	1	3%	34	0%	0	0%	1	0%	0	0%	0	0%	20	56%	1326	18%	11	31%	2719	38%
APR-2020	6	24%	3301	46%	5	20%	3140	43%	1	4%	35	0%	0	0%	0	0%	0	0%	0	0%	8	32%	1404	19%	11	44%	2641	37%
MAY-2020	1	4%	3279	45%	0	0%	3117	43%	0	0%	36	0%	0	0%	0	0%	0	0%	0	0%	13	54%	1482	21%	11	46%	2604	36%
JUN-2020	5	29%	3247	45%	5	29%	3085	43%	0	0%	33	0%	0	0%	0	0%	0	0%	0	0%	4	24%	1587	22%	8	47%	2526	35%

**Definitions:** 

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



Monthly Report

### 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine									
	Init	tial	All							
JAN-2019	27	77%	3697	51%						
FEB-2019	16	55%	3674	51%						
MAR-2019	14	70%	3702	51%						
APR-2019	16	57%	3662	51%						
MAY-2019	27	66%	3689	51%						
JUN-2019	18	86%	3643	51%						
JUL-2019	14	64%	3650	51%						
AUG-2019	22	61%	3626	51%						
SEP-2019	22	81%	3622	51%						
OCT-2019	24	86%	3663	51%						
NOV-2019	25	76%	3671	51%						
DEC-2019	26	96%	3713	52%						
JAN-2020	21	91%	3762	52%						
FEB-2020	33	92%	3781	53%						
MAR-2020	30	83%	3855	54%						
APR-2020	19	76%	3893	54%						
MAY-2020	23	96%	3920	54%						
JUN-2020	12	71%	3933	55%						

### **Definitions:**

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



Monthly Report

[	fosamprenavir atazanavir			darunavir			lopinavir			nelfinavir					ritor	avir		saquinavir									
	Initi	al	All		Init	ial	All	Ir	itial	All		Init	tial	All		Initi	ial	All		Initi	al	All		Initi	al	All	
JAN-2019	0	0%	6	0%	1	8%	1097 40%	5 11	92%	1475	54%	0	0%	140	5%	0	0%	0	0%	0	0%	1	0%	0	0%	9	0%
FEB-2019	0	0%	5	0%	2	18%	1069 40%	5 9	82%	1472	55%	0	0%	138	5%	0	0%	0	0%	0	0%	1	0%	0	0%	9	0%
MAR-2019	0	0%	5	0%	2	40%	1053 39%	5 3	60%	1486	55%	0	0%	132	5%	0	0%	1	0%	0	0%	1	0%	0	0%	7	0%
APR-2019	0	0%	5	0%	1	10%	1027 39%	5 7	70%	1477	56%	2	20%	132	5%	0	0%	2	0%	0	0%	1	0%	0	0%	7	0%
MAY-2019	0	0%	5	0%	1	8%	1033 39%	5 11	92%	1478	56%	0	0%	130	5%	0	0%	2	0%	0	0%	1	0%	0	0%	6	0%
JUN-2019	0	0%	5	0%	0	0%	1001 39%	5 9	100%	1464	57%	0	0%	119	5%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
JUL-2019	0	0%	5	0%	0	0%	981 38%	6	5 100%	1482	58%	0	0%	111	4%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
AUG-2019	0	0%	5	0%	0	0%	968 38%	5 11	92%	1459	57%	1	8%	112	4%	0	0%	1	0%	0	0%	1	0%	0	0%	5	0%
SEP-2019	0	0%	4	0%	1	8%	954 37%	5 12	92%	1481	58%	0	0%	110	4%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
OCT-2019	0	0%	4	0%	1	7%	957 37%	5 13	93%	1489	58%	0	0%	109	4%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
NOV-2019	0	0%	4	0%	0	0%	940 37%	5 3	3 100%	1469	58%	0	0%	101	4%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
DEC-2019	0	0%	4	0%	0	0%	923 37%	5 7	100%	1466	59%	0	0%	100	4%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
JAN-2020	0	0%	2	0%	0	0%	910 37%	6	86%	1466	59%	1	14%	96	4%	0	0%	0	0%	0	0%	1	0%	0	0%	6	0%
FEB-2020	0	0%	2	0%	1	11%	873 36%	5 8	89%	1454	60%	0	0%	96	4%	0	0%	0	0%	0	0%	1	0%	0	0%	6	0%
MAR-2020	0	0%	2	0%	1	10%	860 36%	5 9	90%	1435	60%	0	0%	93	4%	0	0%	0	0%	0	0%	1	0%	0	0%	6	0%
APR-2020	0	0%	2	0%	0	0%	839 36%	5 4	80%	1415	60%	1	20%	93	4%	0	0%	0	0%	0	0%	1	0%	0	0%	6	0%
MAY-2020	0	0%	2	0%	1	10%	835 36%	5 9	90%	1415	60%	0	0%	90	4%	0	0%	0	0%	0	0%	0	0%	0	0%	6	0%
JUN-2020	0	0%	2	0%	2	33%	813 35%	5 4	67%	1391	61%	0	0%	86	4%	0	0%	0	0%	0	0%	1	0%	0	0%	6	0%

Ministry of

Health

# 2.7 Number of Participants on Protease Inhibitor by INGREDIENT

**Definitions:** 

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



Monthly Report

	Initi	ial	All	
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%
JAN-2020	0	0%	1	0%
FEB-2020	0	0%	1	0%
MAR-2020	0	0%	1	0%
APR-2020	0	0%	1	0%
MAY-2020	0	0%	0	0%
JUN-2020	0	0%	1	0%

## 2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

### **Definitions:**

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



HIV/AIDS Drug Treatment Program

Monthly Report

[		dorav	virine		efav	irenz	etra	virine	nevir	apine	rilpiv	irine
	Initi	al	All		Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0	0%	0	0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0	0%	0	0%	2 67%	667 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0	0%	0	0%	3 75%	660 35%	0 0%	223 12%	1 25%	680 36%	0 0%	322 17%
APR-2019	0	0%	0	0%	4 100%	645 35%	0 0%	222 12%	0 0%	677 36%	0 0%	320 17%
MAY-2019	0	0%	0	0%	5 100%	647 35%	0 0%	217 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0	0%	0	0%	3 75%	633 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0	0%	1	0%	2 100%	633 35%	0 0%	209 11%	0 0%	657 36%	0 0%	322 18%
AUG-2019	0	0%	1	0%	2 100%	624 35%	0 0%	205 11%	0 0%	647 36%	0 0%	324 18%
SEP-2019	0	0%	1	0%	4 80%	607 34%	0 0%	207 12%	0 0%	622 35%	1 20%	324 18%
OCT-2019	0	0%	1	0%	6 60%	608 35%	1 10%	209 12%	2 20%	596 34%	1 10%	330 19%
NOV-2019	0	0%	1	0%	5 71%	612 37%	0 0%	208 12%	1 14%	525 31%	1 14%	326 20%
DEC-2019	0	0%	1	0%	3 100%	607 37%	0 0%	203 12%	0 0%	513 31%	0 0%	324 20%
JAN-2020	0	0%	1	0%	2 100%	589 36%	0 0%	202 13%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0	0%	1	0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0	0%	1	0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0	0%	1	0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0	0%	1	0%	1 50%	540 36%	0 0%	194 13%	0 0%	453 30%	1 50%	305 20%
JUN-2020	0	0%	1	0%	2 100%	527 36%	0 0%	190 13%	0 0%	449 30%	0 0%	306 21%

### 2.8 Number of Participants on Non-Nucleosides by INGREDIENT

### **Definitions:**

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



Ministry of

Health



HIV/AIDS Drug Treatment Program

Monthly Report

		bicte	gravir			dolute	egravir			elvite	gravir			mara	viroc			ralteg	gravir	
	Init	ial	All		Init	ial	All		Ini	tial	All		Initi	al	All		Init	tial	All	
JAN-2019	0	0%	16	0%	15	75%	2429	63%	4	20%	729	19%	0	0%	39	1%	1	5%	651	17%
FEB-2019	0	0%	27	1%	16	73%	2431	63%	5	23%	726	19%	0	0%	40	1%	1	5%	651	17%
MAR-2019	0	0%	27	1%	8	62%	2479	64%	5	38%	745	19%	0	0%	38	1%	0	0%	647	17%
APR-2019	0	0%	27	1%	8	57%	2493	64%	3	21%	736	19%	0	0%	36	1%	3	21%	636	16%
MAY-2019	0	0%	27	1%	19	68%	2554	64%	6	21%	746	19%	0	0%	37	1%	3	11%	634	16%
JUN-2019	0	0%	27	1%	10	77%	2556	65%	3	23%	743	19%	0	0%	37	1%	0	0%	624	16%
JUL-2019	0	0%	27	1%	13	81%	2603	65%	3	19%	755	19%	0	0%	38	1%	0	0%	628	16%
AUG-2019	0	0%	27	1%	24	86%	2647	65%	1	4%	755	19%	0	0%	36	1%	3	11%	625	15%
SEP-2019	0	0%	28	1%	7	47%	2648	65%	6	40%	757	19%	0	0%	37	1%	2	13%	627	15%
OCT-2019	0	0%	28	1%	13	87%	2717	66%	1	7%	758	18%	0	0%	34	1%	1	7%	628	15%
NOV-2019	3	13%	88	2%	16	70%	2741	65%	4	17%	770	18%	0	0%	33	1%	0	0%	621	15%
DEC-2019	12	63%	230	5%	6	32%	2717	64%	1	5%	744	18%	0	0%	33	1%	0	0%	606	14%
JAN-2020	9	50%	421	10%	7	39%	2688	62%	0	0%	707	16%	0	0%	32	1%	2	11%	594	14%
FEB-2020	14	52%	602	14%	11	41%	2645	60%	2	7%	654	15%	0	0%	29	1%	0	0%	576	13%
MAR-2020	19	68%	755	17%	7	25%	2624	58%	1	4%	623	14%	1	4%	30	1%	0	0%	562	12%
APR-2020	7	50%	829	18%	6	43%	2591	57%	1	7%	607	13%	0	0%	29	1%	0	0%	544	12%
MAY-2020	10	56%	912	20%	6	33%	2562	56%	2	11%	597	13%	0	0%	27	1%	0	0%	541	12%
JUN-2020	4	31%	1024	22%	9	69%	2543	55%	0	0%	583	13%	1	8%	28	1%	0	0%	538	12%

### 2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

### **Definitions:**

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



# 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

	+ 2	sted PI NRTIs	+ 2	NNRTI NRTIs	+ 2	egrase NRTIs		NRTIs		MDRT		Other
MON-YYYY	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2019	1830	24.75	1481	20.03	3061	41.40	100	1.35	53	0.72	868	11.74
FEB-2019	1802	24.46	1478	20.06	3072	41.69	99	1.34	49	0.67	868	11.78
MAR-2019	1794	24.22	1471	19.86	3124	42.18	98	1.32	50	0.68	870	11.75
APR-2019	1760	23.92	1458	19.82	3135	42.61	100	1.36	48	0.65	857	11.65
MAY-2019	1773	23.91	1448	19.53	3196	43.10	97	1.31	45	0.61	857	11.56
JUN-2019	1738	23.62	1438	19.54	3195	43.42	95	1.29	48	0.65	844	11.47
JUL-2019	1712	23.23	1427	19.36	3236	43.91	92	1.25	48	0.65	855	11.60
AUG-2019	1686	22.89	1402	19.03	3295	44.73	94	1.28	50	0.68	839	11.39
SEP-2019	1697	23.13	1361	18.55	3298	44.94	93	1.27	51	0.70	838	11.42
OCT-2019	1702	23.03	1339	18.12	3357	45.43	93	1.26	52	0.70	846	11.45
NOV-2019	1666	22.69	1272	17.32	3424	46.64	91	1.24	50	0.68	839	11.43
DEC-2019	1643	22.38	1248	17.00	3484	47.45	92	1.25	48	0.65	828	11.28
JAN-2020	1616	21.97	1209	16.43	3563	48.43	87	1.18	56	0.76	826	11.23
FEB-2020	1573	21.46	1154	15.74	3646	49.73	85	1.16	59	0.80	814	11.10
MAR-2020	1541	20.86	1134	15.35	3755	50.83	85	1.15	51	0.69	822	11.13
APR-2020	1525	20.57	1128	15.21	3811	51.40	85	1.15	51	0.69	815	10.99
MAY-2020	1515	20.44	1114	15.03	3835	51.75	83	1.12	51	0.69	813	10.97
JUN-2020	1462	19.79	1088	14.73	3889	52.65	83	1.12	51	0.69	813	11.01

#### **Definitions:**

 ${\bf n}$  is number of participants on the specified regimen class in the specified month % is ratio of n and total number of participants on ART in the specified month



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





### 2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	21	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	15	0	0	2	4	7	530
OCT-2019	13	1	1	4	4	3	380
NOV-2019	17	4	1	1	1	10	520
DEC-2019	12	0	2	4	2	4	350
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380

#### **Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive) **Baseline CD4** is defined as most recent CD4 test before ARV start









## 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Partcipants with PVL test, and never on ART	
JAN-2019	12252	3830	
FEB-2019	12260	3829	
MAR-2019	12290	3859	
APR-2019	12316	3882	
MAY-2019	12332	3883	
JUN-2019	12332	3888	
JUL-2019	12349	3903	
AUG-2019	12381	3920	
SEP-2019	12400	3938	
OCT-2019	12434	3962	
NOV-2019	12456	3971	
DEC-2019	12480	3986	
JAN-2020	12535	4032	
FEB-2020	12566	4049	
MAR-2020	12566	4039	
APR-2020	12544	4015	
MAY-2020	12535	4004	
JUN-2020	12519	3988	

#### **Definitions:**

Patients with PVL test are defined as having at leat one PVL test within previous five years, and not reported deceased/moved Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month










in HIV/AIDS

**3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants** N = 7386 June 2020



BRITISH COLUMBIA


How you want to be treated.

Health

3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants


June 2020


### INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants June 2020

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA







BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2020


### VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2020


VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



### 3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2020

### NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Ago Croup	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST	Age Group 20-34		7	tieated with ARVS
KOOTENAY	35-49	7		*
		9	10	*
	50+	27	39	
	Total HSDA:	43	56	29
KOOTENAY BOUNDARY	0-19			*
BOUNDART	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	74	98	58
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	368	499	282
THOMPSON/CARIBOO/	20-34	18	18	12
SHUSWAP	35-49	70	75	57
	50+	110	179	85
	Total HSDA:	198	272	154
Total HA:		683	925	523
	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		683	925	523
			Ever	Currently
Gender		Alive	treated with ARVs	treated with ARVs
Male		544	737	420
Female		139	188	103
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PVL
Total HA:		523	55	620 35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
EAST	10 years or more	21	13
KOOTENAY	5 years or more	10	6
	<5 years	12	10
	Total HSDA:	43	29
KOOTENAY	10 years or more	47	36
BOUNDARY	5 years or more	16	12
	<5 years	11	10
	Total HSDA:	74	58
OKANAGAN	10 years or more	230	168
	5 years or more	76	64
	<5 years	62	50
	Total HSDA:	368	282
THOMPSON/CARIBOO/	10 years or more	112	83
SHUSWAP	5 years or more	44	40
	<5 years	42	31
	Total HSDA:	198	154
Total HA:		683	523
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	410	300
	5 years or more	146	122
	<5 years	127	101
Total HA:		683	523

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

**Currently treated with ARVs** defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







# 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicans ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicans currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	46	64	14	25
KOOTENAY BOUNDARY	73	123	26	46
OKANAGAN	224	935	60	284
THOMPSON/CARIBOO/SHUSWAI	<b>&gt;</b> 140	521	36	136
Total:	483	1643	136	491

HSDA of	# of Patients seeking Physician's care	
Patient Residency	out of HA	
EAST KOOTENAY	*	
KOOTENAY BOUNDARY	*	
OKANAGAN	*	
THOMPSON/CARIBOO/SHUS	WAP *	
Total:	93	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months **# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs	
FRASER EAST	0-19	6	6	6	
	20-34	33	35	28	
	35-49	97	106	73	
	50+	244	321	191	
	Total HSDA:	380	468	298	
FRASER NORTH	0-19	6	6	*	
	20-34	122	122	*	
	35-49	337	364	*	
	50+	584	916	*	
	Total HSDA:	1049	1408	794	
FRASER SOUTH	0-19	5	5	*	
	20-34	113	115	*	
	35-49	327	370	*	
	50+	565	833	*	
	Total HSDA:	1010	1323	816	
Total HA:		2439	3199	1908	
			Ever	Currently	
	Age Group	Alive	treated with ARVs	treated with ARVs	
	0-19	17	17	11	
	20-34	268	272	194	
	35-49	761	840	601	
	50+	1393	2070	1102	
Total HA:		2439	3199	1908	
			Ever	Currently	
Gender		Alive	treated with ARVs	treated with ARVs	
Male		1849	2449	1459	
		=	750	449	
Female		590	750	449	
Female Currently treated with AR	Vs	590 # of patients 1908	750 Med Age 52	Med CD4 Med PV	/L

### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







## 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
FRASER EAST	10 years or more	225	177
	5 years or more	76	60
	<5 years	79	61
	Total HSDA:	380	298
FRASER NORTH	10 years or more	591	415
	5 years or more	262	218
	<5 years	196	161
	Total HSDA:	1049	794
FRASER SOUTH	10 years or more	581	460
	5 years or more	219	171
	<5 years	210	185
	Total HSDA:	76 79 <b>380</b> 591 262 196 <b>1049</b> 581 219	816
Total HA:	1	2439	1908
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	1397	1052
	5 years or more	557	449
	<5 years	485	407
Total HA:		2439	1908

### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

**Currently treated with ARVs** defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicans ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicans currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	141	512	30	53
FRASER NORTH	251	1578	49	228
FRASER SOUTH	219	1583	49	488
Total:	611	3673	128	769

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA	
FRASER EAST	197	
FRASER NORTH	655	
FRASER SOUTH	442	
Total:	1294	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender VANCOUVER COASTAL Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs	
NORTH SHORE/	0-19	*	*	*	
COAST GARIBALDI	20-34	*	*	*	
	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	342	492	284	
RICHMOND	0-19	*	*	*	
	20-34	*	*	*	
	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	183	232	138	
VANCOUVER	0-19	18	18	7	
	20-34	451	466	306	
	35-49	1357	1519	962	
	50+	2857	4913	2069	
	Total HSDA:	4683	6916	3344	
Total HA:		5208	7640	3766	
			Ever	Currently	
	Age Group	Alive	treated with ARVs	treated with ARVs	
	0-19	22	22	9	
	20-34	510	526	349	
	35-49	1482	1655	1059	
	50+	3194	5437	2349	
Total HA:		5208	7640	3766	
			Ever	Currently	
Gender		Alive	treated with ARVs	treated with ARVs	
Unknown		2	2	0	
Male		4602	6711	3310	
Female		604	927	456	
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PVL	
Total HA:		3766	54	640 35	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







## 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
NORTH SHORE/	10 years or more	191	154
COAST GARIBALDI	5 years or more	89	74
	<5 years	62	56
	Total HSDA:	342	284
RICHMOND	10 years or more	103	71
	5 years or more	37	28
	<5 years	43	39
	Total HSDA:	183	138
VANCOUVER	10 years or more	2875	1966
	5 years or more	1077	787
	<5 years	731	591
	Total HSDA:	4683	3344
Total HA:		5208	3766
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	3169	2191
	5 years or more	1203	889
	<5 years	836	686
Total HA:	-	5208	3766

### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

**Currently treated with ARVs** defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









# 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Physician Residency	# of Physicans ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicans currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBAL	.DI 178	403	56	88
RICHMOND	44	291	11	92
VANCOUVER	622	10945	211	5271
Total:	844	11639	278	5451

	# of Patients ng Physician's care out of HA	
NORTH SHORE/COAST GARIBALDI	*	
RICHMOND	*	
VANCOUVER	*	
Total:	92	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months **# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender VANCOUVER ISLAND Health Authority

			Ever	Currently	
HSDA	Age Group	Alive	treated with ARVs	treated with ARVs	
CENTRAL	0-19	*	*	*	
VANCOUVER	20-34	*	*	*	
ISLAND	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	334	470	269	
NORTH	0-19	*	*	*	
VANCOUVER	20-34	*	*	*	
ISLAND	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	128	170	104	
SOUTH	20-34	75	79	54	
VANCOUVER	35-49	203	235	149	
ISLAND	50+	472	751	366	
	Total HSDA:	750	1065	569	
Total HA:	1	1212	1705	942	
			Ever	Currently	
	Age Group	Alive	treated with ARVs	treated with ARVs	
	0-19	*	*	*	
	20-34	*	*	*	
	35-49	*	*	*	
	50+	*	*	*	
Total HA:		1212	1705	942	
			Ever	Currently	
Gender		Alive	treated with ARVs	treated with ARVs	
Male		1006	1409	787	
Female		206	296	155	
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PVL	
Total HA:		942	55	580 35	

#### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

	Treatment	<b>.</b>	Currently
HSDA	Duration	Alive	treated with ARVs
CENTRAL	10 years or more	192	158
VANCOUVER	5 years or more	73	58
ISLAND	<5 years	69	53
	Total HSDA:	334	269
NORTH	10 years or more	73	60
VANCOUVER	5 years or more	37	29
ISLAND	<5 years	18	15
	Total HSDA:	128	104
SOUTH	10 years or more	435	309
VANCOUVER	5 years or more	164	137
ISLAND	<5 years	151	123
	Total HSDA:	750	569
Total HA:		1212	942
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	700	527
	5 years or more	274	224
	<5 years	238	191
Total HA:	-	1212	942

### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

**Currently treated with ARVs** defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









# 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Physician Residency	# of Physicans ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicans currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	199	874	78	193
NORTH VANCOUVER ISLAND	147	261	50	79
SOUTH VANCOUVER ISLAND	212	1813	46	559
Total:	558	2948	174	831

HSDA of	# of Patients seeking Physician's care	
Patient Residency	out of HA	
CENTRAL VANCOUVER ISI	_AND 50	
NORTH VANCOUVER ISLA	ND 43	
SOUTH VANCOUVER ISLAI	ND 115	
Total:	208	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs	
NORTH EAST	0-19	*	*	*	
	20-34	*	*	*	
	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	40	48	25	
NORTH WEST	20-34	9	10	5	
	35-49	16	32	11	
	50+	43	67	36	
	Total HSDA:	68	109	52	
NORTHERN INTERIOR	0-19	5	5	*	
	20-34	23	24	*	
	35-49	71	88	*	
	50+	91	156	*	
	Total HSDA:	190	273	139	
Total HA:		298	430	216	
			Ever	Currently	
	Age Group	Alive	treated with ARVs	treated with ARVs	
	0-19	6	6	*	
	20-34	33	35	*	
	35-49	107	142	*	
	50+	152	247	*	
Total HA:		298	430	216	
			Ever	Currently	
Gender		Alive	treated with ARVs	treated with ARVs	
Male		181	265	131	
Female		117	165	85	
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PVL	
Total HA:		216	52	550 35	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)









# 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration NORTHERN Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
NORTH EAST	10 years or more	21	*
	5 years or more	14	*
	<5 years	5	*
	Total HSDA:	40	25
NORTH WEST	10 years or more	34	25
	5 years or more	22	17
	<5 years	12	10
	Total HSDA:	68	52
NORTHERN INTERIOR	10 years or more	79	59
	5 years or more	63	46
	<5 years	48	34
	Total HSDA:	190	139
Total HA:		298	216
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	134	96
	5 years or more	99	72
	<5 years	65	48
Total HA:		298	216

### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

**Currently treated with ARVs** defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









## 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries NORTHERN Health Authority

HSDA of Physician Residency	# of Physicans ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicans currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	42	64	8	9
NORTH WEST	83	164	18	35
NORTHERN INTERIOR	115	454	19	187
Total:	240	682	45	231

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA	
NORTH EAST	7	
NORTH WEST	19	
NORTHERN INTERIOR	11	
Total:	37	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





НА	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs	
		6	10	5	
INTERIOR		-			
	KOOTENAY BOUNDARY	6	9	6	
	OKANAGAN	25	41	15	
	THOMPSON/CARIBOO/SHUSWAP	27	49	23	
	Total HA:	64	109	49	
FRASER	FRASER EAST	37	47	32	
	FRASER NORTH	53	89	45	
	FRASER SOUTH	81	114	63	
	Total HA:	171	250	140	
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	24	47	22	
	RICHMOND	9	14	7	
	VANCOUVER	481	865	377	
	Total HA:	514	926	406	
VANCOUVER	CENTRAL VANCOUVER ISLAND	51	80	43	
ISLAND	NORTH VANCOUVER ISLAND	20	29	18	
	SOUTH VANCOUVER ISLAND	42	86	34	
	Total HA:	113	195	95	
NORTHERN	NORTH EAST	11	13	10	
	NORTH WEST	26	57	17	
	NORTHERN INTERIOR	74	113	61	
	Total HA:	111	183	88	
Total:		973	1663	778	

### 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

Gender	Alive	Ever treated with ARVs		rrently with ARVs	
Male	612	1065		485	
Female	361	598		293	
Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL	
Total:	778	52	500	35	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





## 5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer ("booster") given with other antiretrovirals to improve drug exposure. Cobistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy**: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatmentexperienced patients.

**Deceased**: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.







Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It its currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intelence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







## Monthly Report

**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART)**: the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

#### NRTI: see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are preactivated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure ("booster").

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare's trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare's trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.









Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



